Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CDC42 | P60953 | 1/20 | 0.54 |
| ▸ | RAC1 | P63000 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547122 | 1.00 | TDP1 (0.57) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL217765 | 0.93 | TDP1 (0.60) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL8186943 | 0.91 | PTGS2 (0.65) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL2604922 | 0.91 | TDP1 (0.64) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL16300323 | 0.91 | TDP1 (0.64) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL10145224 | 0.88 | TDP1 (0.55) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL554679 | 0.88 | TDP1 (0.55) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL1395993 | 0.88 | PTGS2 (0.63) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL1395995 | 0.88 | PTGS2 (0.63) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL218394 | 0.87 | TDP1 (0.49) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | TDP1 1017/4885L3MBTL1 4793/4885PTGS2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.